General Eye Health & Vision: A Nutritional and Natural-Health Reference
1. Definition and Overview
The eye is the primary sensory organ of vision, and its health encompasses the structural integrity and physiological function of multiple interdependent tissues. The eye is a fluid-filled sphere enclosed by three layers of tissue, most of the outer layer of which is composed of a tough white fibrous tissue called the sclera. At the front of the eye, this opaque outer layer is transformed into the cornea, a specialized transparent tissue that permits light rays to enter the eye. The middle layer of tissue includes three distinct but continuous structures — the iris, the ciliary body, and the choroid. The iris is the colored portion of the eye that can be seen through the cornea; it contains two sets of muscles with opposing actions, which allow the size of the pupil (the opening in its center) to be adjusted under neural control.
The ciliary body is a ring of tissue that encircles the lens and includes a muscular component important for adjusting the refractive power of the lens, and a vascular component (the ciliary processes) that produces the fluid filling the front of the eye. The cornea, iris, ciliary body, and lens all play a role in transmitting and focusing light onto the sensory component of the eye, the retina. Structures such as the choroid, aqueous and vitreous humor, and the lacrimal system are important for physiological balance, appropriate pressure maintenance, and nourishment of ocular tissues.
Visual acuity relies on proper refraction — or bending — of light passing through structures of varying densities as the light is transmitted through the cornea, aqueous humor, lens, and vitreous humor before striking the retina. The lens is the adjustable component of the refractive system: its shape is altered by the contraction or relaxation of the ciliary muscle to focus on objects that are near or far.
Only the innermost layer of the eye, the retina, contains neurons that are sensitive to light and are capable of transmitting visual signals to central targets. The retina is comprised of two types of photoreceptor cells: rods and cones. Rods are the cells primarily responsible for scotopic vision, or low-light vision. Rods are the more abundant cell type and reach their maximum density approximately 15 to 20 degrees from the fovea — the small depression in the retina where visual acuity is highest. There are approximately 90 million rod cells in the human retina. The cones confer color vision and high spatial acuity and are the cell type most activated at higher light levels. The fovea has the highest density of cones and is free of rods. The human retina contains approximately 6 million cone cells.
2. Major Conditions Affecting Eye and Vision Health
Globally, approximately 250 million people suffer from varying degrees of vision loss. Leading causes include cataract, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy. These conditions disproportionately affect older adults, and with an ageing population, the number of affected individuals is predicted to increase exponentially. Whilst the aetiology of age-related eye disease is complex and multifactorial, oxidative stress has been implicated as a common causative mechanism.
2.1 Age-Related Macular Degeneration (AMD)
AMD is a leading cause of irreversible visual loss in the elderly population, affecting millions of people worldwide, and has a substantial effect on quality of life in older individuals. The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of AMD, the most common cause of blindness in older Americans.
2.2 Cataract
Cataracts are characterized by the gradual opacification of the normally clear lens of the eye, which alters light refraction, therefore leading to blindness if left untreated. As the lens ages, conformational changes to lens proteins occur with subsequent aggregation, leading to a progressive loss of transparency and associated vision loss. Oxidation reactions within the lens are thought to be a key factor in this process.
2.3 Glaucoma
Glaucoma is a major ocular neurodegenerative disease and a leading cause of irreversible blindness worldwide, with prevalence projected to exceed 110 million by 2040. Although lowering intraocular pressure (IOP) remains the only proven treatment, glaucoma arises from a complex interplay of genetic, local, and systemic factors — including oxidative stress, vascular dysregulation, mitochondrial dysfunction, and neuroinflammation.
2.4 Vitamin A Deficiency-Related Conditions
Vitamin A's active all-trans retinol metabolite generates rhodopsin for light perception in the eye. Rhodopsin is involved in the dark adaptation process, allowing humans to see in faint light. Vitamin A deficiency (VAD) causes night blindness — resulting in challenges performing tasks in faint light or at night — and night blindness is the first symptom of VAD, which can lead to blindness if left untreated.
The clinical spectrum of VAD ocular signs includes: night blindness (XN), conjunctival xerosis (X1A), Bitot's spots (X1B), corneal xerosis (X2), corneal ulcer covering less than one-third of the cornea (X3A), corneal ulcer covering at least one-third of the cornea known as keratomalacia (X3B), and corneal scarring (XS).
3. Contributing and Associated Risk Factors
3.1 Age and Genetics
Age and genetic make-up are the most important risk factors for AMD identified to date.
3.2 Smoking
There is reasonably consistent evidence that smoking cigarettes results in increased risk of AMD. Smoking is a major global public health concern and contributes to ocular diseases such as cataracts and AMD through ischemic and oxidative mechanisms. Smoking is a well-documented risk factor for cataracts. The oxidative stress caused by smoking can damage the proteins and fibers in the lens, leading to clouding. Studies have shown that smokers are significantly more likely to develop cataracts than non-smokers. With regard to glaucoma, a large prospective cohort study involving more than 100,000 participants and a recent systematic review and meta-analysis reported no significant association between smoking and primary open-angle glaucoma (POAG) incidence, while conversely, other population-based studies and a meta-analysis identified smoking as a risk factor for glaucoma development. The evidence linking smoking to glaucoma therefore remains inconsistent.
3.3 Cardiovascular and Metabolic Factors
An updated meta-analysis highlights the significance of modifiable risk factors for AMD, including smoking, hypertension, cardiovascular diseases, and diabetes. Risk factors with moderate and consistent associations for AMD were higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen. AMD is the leading cause of blindness in Western countries.
3.4 Ultraviolet Light Exposure
Prolonged exposure to UV radiation from sunlight can increase the risk of cataracts. UV rays can damage the proteins in the lens and promote oxidative stress. The effect of ozone depletion and resultant increased exposure to UV-B may result in a sizable increase in the number of persons with cortical cataracts. In the face of these data, the use of hats with brims and protective (UV-B filtering) lenses may be warranted as an approach to reduce the risk of cataract.
3.5 Systemic Conditions
A comprehensive review highlights the crucial roles of essential nutrients in maintaining eye well-being. Nutrient deficiencies have significant consequences, leading to various eye-related issues, from night blindness to age-related conditions such as cataracts and macular degeneration.
3.6 Oxidative Stress as a Unifying Mechanism
A wide range of evidence supports the involvement of oxidative stress in the development and progression of AMD. Established risk factors for AMD, such as aging, smoking, and light exposure, have been shown to contribute to cumulative cellular oxidative injury. Oxidative stress has been proposed as a common underlying mechanism of cataractogenesis as well.
4. Nutrients Studied in Relation to Eye Health
4.1 Vitamin A (Retinol) and Carotenoid Precursors
Role and Deficiency Consequences
Vitamin A plays an important role in vision. To see the full spectrum of light, the eye needs to produce certain pigments for the retina to work properly. Vitamin A deficiency stops the production of these pigments, leading to night blindness. The eye also needs vitamin A to nourish other parts, including the cornea. Without enough vitamin A, the eyes cannot produce enough moisture to keep them properly lubricated.
Vitamin A deficiency is the leading cause of preventable blindness in children worldwide. An estimated 250,000 to 500,000 children become blind every year because of it.
Scientific Evidence
Vitamin A supplements can reverse night blindness and can help the eyes become lubricated again. However, vision loss caused by scarring from corneal ulcers cannot be reversed. The evidence for supplementation in the context of frank deficiency is strong and well-established; however, in populations with adequate intake, the benefit of additional vitamin A specifically for age-related conditions is less clearly supported.
4.2 Lutein and Zeaxanthin
Nature and Dietary Sources
Lutein and zeaxanthin are carotenoids, a class of plant-derived vitamins; both are present in leafy green vegetables and, when consumed, accumulate in the retina. Like beta-carotene, lutein and zeaxanthin are antioxidants with activity in the retina.
Scientific Evidence — AREDS and AREDS2
A major conclusion from the AREDS was that daily, long-term supplementation with vitamin C (500 mg), vitamin E (400 IU), beta-carotene (15 mg), zinc (80 mg, as zinc oxide), and copper (2 mg, as cupric oxide) reduced the relative risk of progression to late-stage AMD from 28% (observed with placebo) to 20% at five years, in people with at least intermediate AMD.
In 2006 the National Eye Institute launched AREDS2, a five-year study designed to test whether the original AREDS formulation could be improved by adding omega-3 fatty acids; adding lutein and zeaxanthin; removing beta-carotene; or reducing zinc. The AREDS2 formula, which substituted antioxidants lutein and zeaxanthin for beta-carotene, was shown to be more effective at reducing risk of AMD progression, compared to the original formula.
In AREDS2, begun in 2006, researchers compared the beta-carotene formulation to one with 10 mg lutein and 2 mg zeaxanthin instead. At the end of the five-year period, the researchers concluded that lutein and zeaxanthin did not increase risk for lung cancer, and that the new formulation could reduce the risk of AMD progression by about 26%.
Formulations containing lutein and zeaxanthin and no beta-carotene had an 18% reduction in developing advanced AMD compared to participants who took the AREDS2 formula with beta-carotene and no lutein or zeaxanthin. Beta-carotene was shown to compete with lutein and zeaxanthin, as individuals who took all three nutrients had lower levels of circulating lutein and zeaxanthin.
When all subgroup analyses evaluating the effect of lutein/zeaxanthin supplementation on progression to late AMD are inspected, point estimates are uniformly in the direction of a protective effect. For safety reasons, especially for current and former smokers, it is important to have an AREDS-type formulation without beta-carotene. The totality of evidence from AREDS2 and other studies suggest that lutein/zeaxanthin could be more appropriate than beta-carotene for the AREDS2 formulation.
Regarding cataracts, observational data suggest that the risk of cataracts can be reduced by a diet that contains optimal levels of vitamins C and E, the carotenoids lutein and zeaxanthin, and the daily use of multivitamin supplements. However, RCTs that have compared antioxidant vitamin supplements to an inactive placebo or no supplement have been unable to detect any effect on cataract development, indicating that the observational–trial evidence gap remains to be resolved.
A Mendelian randomization and observational review found strong evidence for the association between current smoking and cataract, highly suggestive evidence for fish consumption and AMD, and suggestive evidence for dietary factors like omega-3 polyunsaturated fatty acids, lutein, zeaxanthin, and vitamin C in relation to cataract.
4.3 Vitamin C (Ascorbic Acid)
Vitamin C is an antioxidant that protects the eyes from oxidative stress. The lens of the eye maintains exceptionally high concentrations of vitamin C. Oxidative stress has been proposed as a common underlying mechanism of cataractogenesis. Experimental and observational data suggest that micronutrients like vitamin C with antioxidant capabilities may retard the development of age-related cataract.
However, the clinical evidence is nuanced. The available evidence suggests that while maintenance of vitamin C levels is required to prevent oxidative damage to the lens, excessive administration of vitamin C appears to be linked to cataract formation in some animal models. Findings from epidemiological studies alone cannot be utilized to make conclusive statements about the impact of vitamin C supplementation on cataract formation. In assessing the link between vitamin C supplement consumption and cataract risk, unmeasured lifestyle differences may account for identified differences in epidemiological studies. Further research is necessary to resolve the lack of cohesion in the current literature.
As part of the AREDS formulation (500 mg vitamin C, 400 IU vitamin E, beta-carotene, zinc, and copper), estimates of odds reductions were about 25% for zinc alone and 37% for zinc plus antioxidants for AMD participants in the higher-risk categories. Odds reductions for the antioxidants plus zinc treatment were 24% for Category 3 participants and 48% for Category 4 participants. This analysis suggests that the reduction in risk of visual acuity loss observed with the antioxidant plus zinc formulation may be a result of the reduction in risk of progression to advanced AMD.
4.4 Vitamin E (Tocopherol)
Vitamin E is an antioxidant that protects the eyes from oxidative stress. It was included alongside vitamin C, beta-carotene, and zinc in the original AREDS formulation that demonstrated benefit in slowing AMD progression. Vitamin E is among the dietary antioxidants assessed for preventing and managing cataracts. The evidence for vitamin E supplementation in isolation for eye disease is considered preliminary; its demonstrated benefit comes mainly from multi-nutrient AREDS-type combination trials rather than standalone studies.
4.5 Zinc
Zinc is an essential trace mineral for ocular health due to its involvement in the functioning of enzymes responsible for various visual processes. It is particularly vital for maintaining the retina's health, the light-sensitive tissue at the back of the eye. Zinc is crucial for the function of enzymes involved in visual processes.
In the AREDS trial, the four treatment interventions included an oral total daily supplementation of antioxidants (500 mg of vitamin C, 400 IU of vitamin E, and 15 mg of beta-carotene), or zinc (80 mg of zinc as zinc oxide and 2 mg of copper as cupric oxide to prevent potential anemia), or the combination of antioxidants and zinc, or placebo. Zinc alone and zinc combined with antioxidants both showed statistically significant reductions in AMD progression compared to placebo. The AREDS2 study showed that lowering the amount of zinc had no effect on AMD progression.
4.6 Omega-3 Fatty Acids (DHA and EPA)
Omega-3 fatty acids (FAs) are crucial polyunsaturated FAs that humans must acquire from food sources because they cannot produce them internally. These FAs are classified as short-chain (e.g., alpha-linolenic acid) and long-chain (e.g., docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]).
Omega-3 and AMD
Adding omega-3 fatty acids did not improve the AREDS combination of nutritional supplements commonly recommended for AMD. The plant-derived antioxidants lutein and zeaxanthin also had no overall effect on AMD when added to the combination. In the AREDS2 trial, adding omega-3 fatty acids or lutein + zeaxanthin to the AREDS formula had no additional overall effect on the risk of advanced AMD.
Omega-3 and Dry Eye Disease
The evidence for omega-3 supplementation for dry eye is inconsistent. The best quality RCT found that omega-3 supplementation does not improve dry eye symptoms or function, while smaller RCTs suggest statistically significant benefits in symptom scores that are not always clinically relevant. Eleven RCTs of omega-3 (with both EPA and DHA) reported patient-oriented outcomes. The best quality RCT examined 535 patients (mean age 58) with moderate symptoms of dry eye disease taking omega-3 (2000 mg EPA and 1000 mg DHA per day) versus placebo; at one year there was no difference in symptom scores, patient function, objective measures, or adverse events.
By contrast, a meta-analysis of smaller trials found a different signal: this meta-analysis provides evidence that omega-3 FA supplementation significantly improves dry eye symptoms and signs in patients with dry eye disease, and indicates that omega-3 FA supplementation may be an effective treatment. However, this finding is tempered by the large, high-quality negative RCT noted above, and the overall evidence remains mixed.
Based on clinical evidence, dietary essential fatty acids have demonstrated potential efficacy, especially in addressing inflammatory reactions. Research has indicated that omega-3 FAs may alter the composition of the lacrimal gland and enhance lacrimal secretion.
A large retrospective observational study also found that women who consumed 5 to 6 servings of tuna fish per week (high in omega-3) had a 66% reduction in dry eye disease compared with women who consumed 2 or fewer servings a week, though observational studies of this kind cannot establish causality.
Omega-3 and Intraocular Pressure
Omega-3 EFA deprivation may predispose individuals to ocular disease in later life, and the potential benefit of omega-3 fatty acid supplementation has undergone evaluation in clinical trials in eye diseases that show an increased prevalence with age, particularly AMD and dry eye disease. The effect of polyunsaturated fats on glaucoma remains inconsistent and warrants source- (plant vs. animal) and substitution-based analyses.
5. Herbs and Botanical Ingredients
5.1 Bilberry (Vaccinium myrtillus)
Traditional Use
Bilberry fruits are an important part of local diets in many countries and are used as a medicinal herb to treat various disorders. Extracts from the fruits are often a part of eye health-promoting supplements. The extracts from the fruits and leaves have a long-standing tradition of use for vision-related ailments, elevated blood sugar levels, and several different cardiovascular disorders. Modern research of bilberry was partly based on its use by British World War II pilots, who noticed that their night vision improved when they ate bilberry jam prior to night bombing raids.
Proposed Mechanisms
Bilberry represents one of the richest natural sources of anthocyanins. Anthocyanins have been shown to regenerate the rhodopsin present in retinal photoreceptor cells. The anti-inflammatory and antioxidant effects give bilberry potential value in the prevention and treatment of conditions associated with inflammation, dyslipidemia, hyperglycemia, and increased oxidative stress.
Scientific Evidence
Overall, the three most referenced indications for bilberry — type 2 diabetes mellitus, vision disorders, and circulatory diseases — all include contradictory results with no clear conclusion as to the benefits and recommended dosages. Moreover, the indications for vision disorders originate from unproven or false claims that have been repeated in research since earlier decades. In recent studies of bilberry extract's effects on health, the most compelling evidence is its reduction of retinal inflammation — although studies have been small and mostly conducted in lab animals.
A clinical trial in patients with normal-tension glaucoma (NTG) assessed bilberry anthocyanins: in the anthocyanin treatment group (132 eyes of 132 patients), the mean baseline best-corrected visual acuity (BCVA) improved after anthocyanin treatment, and the visual field mean deviation also improved significantly (p = 0.001). While these results are promising, this was a single-center trial with limitations. Overall, the evidence for bilberry in eye health remains preliminary, with no large, well-powered RCTs confirming clinical benefit.
5.2 Eyebright (Euphrasia officinalis)
Traditional Use
Eyebright is an herb with a long history of medicinal use for eye ailments. Preliminary evidence suggests that eyebright may benefit inflamed, irritated eyes, but more high-quality human studies are needed. It has been used in traditional herbal medicine in Europe for centuries, particularly for minor eye ailments like redness and irritation.
Scientific Evidence
Though preliminary evidence suggests that eyebright may benefit inflamed, irritated eyes, more high-quality human studies are needed. The current evidence base for eyebright as a standalone intervention for eye health conditions is very limited; no robust clinical trials in human populations have been identified in the peer-reviewed literature establishing efficacy.
5.3 Ginkgo biloba
Traditional Use
Ginkgo biloba has been used for hundreds of years to treat various disorders such as asthma, vertigo, fatigue, tinnitus, and circulatory problems. Ginkgo leaves contain two main active ingredients: flavonoids and terpenoids.
Proposed Mechanisms and Preclinical Evidence
Ginkgo biloba extracts exert considerable antioxidant and anti-inflammatory actions. Ginkgo biloba extract significantly enhances retinal ganglion cell (RGC) survival following oxidative stress in vitro (p < 0.001). Rat models of hypoxic optic nerve injury demonstrate significant RGC density improvements following systemic Ginkgo biloba extract supplementation, an effect attributable to its antioxidant and anti-apoptotic properties.
Scientific Evidence in Glaucoma
Ginkgo biloba is one of the most studied supplements for glaucoma, with at least four randomized clinical trials. The first, in 2003, found that for low-pressure glaucoma patients, 40 mg of ginkgo biloba extract three times daily (120 mg total daily dose) could improve pre-existing visual field loss after four weeks. Although the trial had its shortcomings — a short duration and only 27 patients — the fact that field loss could be improved was considered notable. Subsequent trials have also found improvement in blood microcirculation to the optic nerve and reduction of oxidative stress in the bloodstream.
After Ginkgo biloba extract (GBE) treatment in one controlled trial, a significant improvement in visual field indices was recorded. However, most botanical compounds investigated for eye diseases are still in the pre-clinical stage, with studies focusing on cells or animal models. Several compounds such as lutein, zeaxanthin, saffron, Ginkgo biloba extract, and danshen have been tested in clinical trials, but the evidence for GBE from these trials remains preliminary and the trials are generally small and of short duration.
5.4 Saffron (Crocus sativus)
Traditional Use
Saffron has been used in Persian, Ayurvedic, and Mediterranean traditional medicine for a broad range of conditions. Its use specifically for eye complaints appears in classical Persian medical literature, where it was applied topically or taken internally for visual disorders.
Scientific Evidence
Saffron is well known for its antioxidant benefits, in addition to IOP-modulating and psycho-modulatory effects. Saffron has been tested in clinical trials for ocular disease. The evidence is emerging and based largely on small trials. Overall, the body of human clinical trial data for saffron in eye health is limited but promising, and larger, well-controlled trials are needed.
6. Dietary Patterns and Lifestyle Factors
6.1 Overall Dietary Quality
Growing evidence suggests that lifestyle factors — particularly dietary patterns and specific nutrients, as well as exercise, smoking, sleep, alcohol, and caffeine — may modulate underlying pathophysiological mechanisms of glaucoma. For instance, dietary antioxidants (e.g., carotenoids, vitamins C and E, and polyphenols) and one-carbon-pathway nutrients (e.g., folate and vitamins B-2/B-6/B-12) support glutathione regeneration and homocysteine control, thereby mitigating oxidative and nitrosative stress implicated in retinal ganglion cell (RGC) injury.
6.2 Leafy Green Vegetables and Dietary Nitrate
Higher dietary nitrate from leafy greens is consistently associated with lower primary open-angle glaucoma risk, aligning with nitric-oxide-mediated endothelial support and more stable ocular perfusion pressure.
6.3 Fish Consumption
There is highly suggestive evidence for fish consumption and reduced risk of AMD, consistent with the hypothesis that dietary omega-3 fatty acids derived from marine sources support retinal health.
6.4 Flavonoids and Carotenoids
Flavonoids (anthocyanins and flavanols), carotenoids (lutein/zeaxanthin), and B vitamins have strong biological rationale for glaucoma prevention but have limited support from long-term, large population-based studies.
6.5 Smoking Cessation
Smoking contributes to ocular diseases such as cataracts and AMD through ischemic and oxidative mechanisms. Smoking and alcohol use are frequently coupled with poorer diet quality (e.g., lower vegetable intake) and heightened oxidative stress, which may exacerbate glaucomatous neurodegeneration.
6.6 Physical Activity and Sleep
Consistent protective effects of aerobic exercise and high-quality sleep may be associated with favorable metabolic profiles and ocular perfusion, potentially mitigating retinal ganglion cell loss.
6.7 UV Protection
The use of hats with brims and protective UV-B filtering lenses may be warranted as an approach to reduce the risk of cataract.
6.8 Limitations in the Current Lifestyle Evidence Base
Much of the current literature is constrained by cross-sectional designs, reliance on self-reported food frequency questionnaires, and insufficient use of structural endpoints such as retinal nerve fiber layer imaging. The effects of nutrients and diet on cortical and nuclear cataracts appear to be of small magnitude in the current body of research.
References
- Ludwig PE, Jessu R, Czyz CN. Physiology, Eye. StatPearls [Internet]. NIH/NCBI Bookshelf, 2023.
- Purves D et al. Anatomy of the Eye. Neuroscience, 2nd edition. Sinauer Associates, 2001. NIH/NCBI Bookshelf.
- Risk factors for age-related macular degeneration — Meta-analysis. PMC/NIH, 2025.
- Chakravarthy U et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. PubMed, 2010.
- NIH National Eye Institute. NIH study confirms benefit of supplements for slowing AMD. NEI, 2022.
- NIH National Eye Institute. About AREDS and AREDS2. NEI Clinical Trials.
- AREDS2 Research Group. Secondary Analyses of the Effects of Lutein/Zeaxanthin on AMD Progression. AREDS2 Report No. 3. JAMA Ophthalmol. 2014;132(2):142–149. PMC.
- Age-Related Eye Disease Study Research Group. AREDS Report No. 8: High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for AMD. PMC/NIH.
- Nutrition and Eye Health. PMC/NIH, 2019.
- Unveiling the Spectrum of Ophthalmic Manifestations in Nutritional Deficiencies: A Comprehensive Review. PMC/NIH, 2024.
- The eye signs of vitamin A deficiency. PMC/NIH.
- American Academy of Ophthalmology. What Is Vitamin A Deficiency? AAO, 2024.
- Omega-3 supplements for dry eye. PMC/NIH, 2018.
- Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMC/NIH, 2023.
- Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. PubMed, 2019.
- Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes. PMC/NIH, 2016.
- Vitamin C and the Lens: New Insights into Delaying the Onset of Cataract. PMC/NIH, 2020.
- Oxidative Stress and Cataract Formation: Evaluating the Efficacy of Antioxidant Therapies. PMC/NIH, 2024.
- Bilberries: Curative and Miraculous – A Review on Bioactive Constituents and Clinical Research. PMC/NIH, 2022.
- Ginkgo biloba Extract and Bilberry Anthocyanins Improve Visual Function in Patients with Normal Tension Glaucoma. PMC/NIH, 2012.
- Ginkgo biloba: An adjuvant therapy for progressive normal and high tension glaucoma. PMC/NIH, 2012.
- Botanical Compounds: Effects on Major Eye Diseases. PMC/NIH, 2013.
- Nutraceuticals and neuroprotection for glaucoma — introducing the NP-10 System. PMC/NIH, 2025.
- Lifestyle Exposures and Eye Diseases in Adults. PMC/NIH, 2008.
- Impact of smoking on glaucoma. PMC/NIH, 2024.
- Diet, Exercise, and Lifestyle in Glaucoma: Current Evidence and Future Perspectives. PMC/NIH, 2025.
- Knowledge and attitudes about vitamin A consumption and its relationship with night blindness. PMC/NIH, 2024.
Go back